Cortexyme to Present at Annual Biomarkers for Alzheimer’s Disease Summit

Rhea-AI Summary

Cortexyme, Inc. (Nasdaq: CRTX) is advancing a pivotal trial for Alzheimer's disease, with top-line data expected by mid-November 2021. The company will present at the Annual Biomarkers for Alzheimer’s Disease Summit on August 25, 2021, sharing new findings on P. gingivalis infection and its connection to Alzheimer's pathology. Speaker Leslie Holsinger, Ph.D. will cover the pivotal Phase 2/3 GAIN Trial, demonstrating the role of neuroinflammation and novel biomarkers in patients with mild to moderate Alzheimer's disease.

Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s disease with top-line data expected by mid-November 2021 and a growing pipeline of therapeutics for degenerative diseases, will participate as a featured speaker covering its pivotal Phase 2/3 GAIN Trial of atuzaginstat and the upstream role that P. gingivalis plays in key pathologies of Alzheimer’s disease at the upcoming Annual Biomarkers for Alzheimer’s Disease Summit taking place virtually August 24-26, 2021. Cortexyme will present new data demonstrating further evidence of P. gingivalis infection of the central nervous system in Alzheimer’s disease as demonstrated by analysis of anti-P. gingivalis antibodies in cerebrospinal fluid from the GAIN trial.

Annual Biomarkers for Alzheimer’s Disease Summit Details

Topic: Use of Novel Biomarkers of P. Gingivalis Infection & Neuroinflammation in the GAIN Trial: An Ongoing Phase 2/3 Clinical Trial Assessing the Activity of Atuzaginstat in Patients with Mild to Moderate Alzheimer’s Disease

• Speaker: Leslie Holsinger, Ph.D., Cortexyme’s Executive Vice President, Research and Development
• Day/Time: Wednesday, August 25, 2021, at 2:10 p.m. ET followed by a live Q&A at 3:40 p.m. ET

About Cortexyme

Cortexyme, Inc. (Nasdaq: CRTX) is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer’s and other degenerative diseases. The company is advancing its disease-modifying pivotal GAIN Trial in mild to moderate Alzheimer's disease with top-line data expected by mid-November 2021, in addition to growing a proprietary pipeline of first-in-class small molecule therapeutics for Parkinson’s disease, periodontitis, and other diseases with high unmet clinical need. Cortexyme’s lead program targets a specific, infectious pathogen called P. gingivalis found in the brain and other organs and tied to degeneration and inflammation in humans and animal models. The company’s causation evidence for Alzheimer’s disease and the mechanism of its novel therapeutic has been independently replicated and confirmed by multiple laboratories around the world, as well as published in peer-reviewed scientific journals. To learn more about Cortexyme, visit www.cortexyme.com or follow @Cortexyme on Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210818005203/en/

FAQ

What is the focus of Cortexyme's GAIN Trial for Alzheimer's disease?

Cortexyme's GAIN Trial focuses on assessing the activity of atuzaginstat in patients with mild to moderate Alzheimer's disease while investigating the role of P. gingivalis.

When will Cortexyme present at the Annual Biomarkers for Alzheimer’s Disease Summit?

Cortexyme will present on August 25, 2021, at 2:10 p.m. ET.

What new data will Cortexyme present regarding Alzheimer's disease?

Cortexyme will present new data on P. gingivalis infection in the central nervous system and its link to Alzheimer's disease, derived from the GAIN Trial.

What is the significance of the <i>P. gingivalis</i> infection in Alzheimer's disease research?

P. gingivalis is linked to neuroinflammation and degeneration in Alzheimer's disease, making it a crucial target for Cortexyme's therapeutic approaches.

What are the upcoming data expectations for Cortexyme's GAIN Trial?

Top-line data from Cortexyme's GAIN Trial is expected by mid-November 2021.